drugset
drugset / Trial / NCT00023166

Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

NCT00023166 ↗

Phase 1 Terminated Enzon Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Studies of PEG-paclitaxel have been terminated

Timeline

Start
2001-05
Primary completion
—
Completion
2002-05

Drugs

EvaluationDrugModalityDoseRoute
Subject PEG-paclitaxel Unknown — —

Indications

lymphoma metastatic neoplasm